Gabapentin Tablet, Film Coated
Product Images NDC 60760-066

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-066). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gaba (Gabapentin 60760 066 90)

This is a description of a medication called Gabapentin. It comes in tablet form with a strength of 600mg. The NDC (National Drug Code) for this medication is 60760-066-90. The tablets are manufactured by Strides Shasunlimited in India. The medication should be used as directed and stored at controlled room temperature between 15°C and 30°C (59°F-86°F). The description also includes various lot and RX numbers, but the specific information provided is not clear.*

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

This text is a mathematical equation used to calculate creatinine clearance (ClCr) for patients. The equation takes into account the patient's age, weight, and serum creatinine levels. It also includes a coefficient of 0.85 for female patients. ClCr is an important measure in determining kidney function and is commonly used in clinical practice.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

This is a table showing the mean pain scores for a 4-week fixed dose period, with two treatment groups: a placebo group and two different doses (1800 mg/day and 2400 mg/day) of gabapentin. There are scores for baseline and seven subsequent time points.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

This appears to be the result of a study showing the proportion of patients who experienced a reduction in pain score. The study was about Controlled PHN Studies. Two studies were conducted and the percentage of responders in each study was 32% and 34% respectively. There are also some numerical values in GBP currency listed. The context of these values cannot be determined from the provided text.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.